ArticleCancers2024

A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.

Filip Janku et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.